Ruti Aga Banned for Six Years: Fake Prescription Issued by Family Member Alters the Future of a Stellar Career

Addis Ababa/London: Ethiopian long-distance runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The ban is effective from 10 September, the date she was provisionally suspended. The 32-year-old Aga, a former Tokyo Marathon winner and three-time World Marathon Majors runner-up, will now be out of competition until approximately the age of 38. For an elite female marathoner, this is effectively the end of her career. The case goes far beyond substance use. The AIU investigation found that Aga presented a prescription in her defence that had been prepared by a family member. That "doctor" was not registered with any medical council, and the clinic named on the prescription did not actually exist. The clinic administration explicitly disowned the document and stated that no such document had ever been issued by them. This forgery sends a clear message in the sporting world: tampering with medical documents is now as serious as the use of a prohibited substance itself. In Aga's case, a two-year sanction for the presence violation and a four-year sanction for tampering were combined—six years in total. This arithmetic tells a story in itself. The panel clearly rejected the "no significant fault" mitigation that would otherwise have reduced the presence sanction. In other words, the forged document itself provided circumstantial evidence of concealment intent. But the most important aspect of this story, which most media reports either ignored or presented incorrectly, is the substance category. Methylprednisolone is not a "prohibited steroid." It is a glucocorticoid, falling under category S9 of the World Anti-Doping Agency (WADA) Prohibited List, not S1 (anabolic steroids). This distinction is not merely technical—it is the legal hinge of the entire case. Under the current Prohibited List, S9 glucocorticoids are prohibited only in-competition, and only when administered by injection, oral, or rectal routes. Intra-articular or peri-articular injection for knee synovitis—a standard sports-medicine treatment in distance running—is entirely legal out-of-competition. It becomes a violation only if residues are present in a sample during competition. The testing window for a road race opens at 23:59 the night before the race, so a glucocorticoid injection given days earlier can still be caught. This means Aga had a legitimate defence pathway available. Had she presented genuine medical records and explained the timing and route of the injection, the case could potentially have ended with less than a two-year suspension—or not been built at all. But by fabricating the prescription, she destroyed the one defence that could have worked. The sequence of events is clear. In March, Aga won a half marathon in China. A sample taken after that race tested positive for methylprednisolone. Aga's defence claimed she had a knee injury and had sought treatment. The investigation revealed that the "doctor" claiming to have treated her was a family member with no medical registration. He claimed to have used "an old prescription pad from a former workplace." The clinic named on the prescription did not exist—and the clinic explicitly disowned the document. These are three independent verification failures. This was not a filing error—it was the signature of an athlete operating without a credentialed team physician. The AIU investigation also included an interview in which Aga allegedly provided misleading information. That interview formed the basis for the four-year tampering sanction. This was not a document-only case—it was also based on statements made during questioning. The AIU said in a statement on Thursday that the athlete attempted to distort the investigation through documents. Ruti Aga is 32 years old. In women's marathoning, this is the "late peak/beginning of decline" phase. A six-year ban puts her entirely out of the 2028 Olympic cycle. By the time she is eligible to return, she will be approximately 38. Given the depth of Ethiopian women's marathoning, a 38-year-old returnee with a doping record has virtually zero chance of national team selection. Ethiopia's women's marathon boasts world-record-class athletes who have reached the sub-2:12 level, along with multiple sub-2:16 performers. A 2:18-2:20 class athlete is not automatically selectable. Aga's removal is invisible at the national-team level. It has no measurable effect on medal capacity. Aga's career was genuinely stellar. Second place at the 2026 Berlin Marathon (approximately 2:18:34) and first place at the 2026 Tokyo Marathon (approximately 2:20:40). Additionally, three second-place finishes at World Marathon Majors. These achievements establish her as a genuinely world-class marathoner. But after 2026, her pattern changed—selective Major racing and appearances at Asian label races. This is a classic high-appearance-fee, low-race-count model for a 2:18-2:20 marathoner. The Chinese half-marathon circuit functions as a lucrative, low-risk income tier for East African marathoners. But that same tier is now the AIU's highest-yield testing ground—the appearance-fee economy and the testing economy are colliding in the same races. The sanction arithmetic is standard: 2 years for the presence violation + 4 years for tampering = 6 years. Backdating to 10 September is a procedural benefit, not a reduction. Provisional suspension time counts against the ban; the athlete gains nothing in real terms. This case exposes a major systemic failure. Knee injury is a known issue in distance running. Injured marathoners face strong incentives to mask pain—particularly to protect appearance-fee income. Glucocorticoids are the cheapest, most available tool for this. And the surrounding medical network is informal. It is also possible that the knee problem was chronic and career-long, rather than an acute March event. The attempt to manufacture a paper trail suggests a repeated pattern of informal treatment rather than a single lapse. If the media called methylprednisolone a "steroid," it is wrong and affects the interpretation of the case. There is a fundamental difference between anabolic steroids and glucocorticoids: anabolic steroids are associated with muscle-building; glucocorticoids are anti-inflammatory. A six-year ban for a glucocorticoid—which has no proven endurance performance benefit—is a striking outcome that will be cited both as evidence of AIU rigor and as evidence of disproportionate enforcement against African road runners. Appeal risk is live but low-value. A Court of Arbitration for Sport (CAS) appeal window (typically about 21 days from the reasoned decision) exists; the forgery finding is document-based and hard to overturn. The disqualification scope is unstated but almost certainly includes the March race result and its prize money, plus forfeiture of any ranking points accrued after that date. This is a textbook "career-terminal, self-inflicted" case. At 32, with a six-year ban running to roughly age 38, the sanction is functionally a lifetime ban for elite purposes. The athlete's own conduct—not the substance—converted a likely two-year absence into career death. The knee injury is the true root cause, and it is a systemic rather than individual signal. Her commercial standing is now bifurcated: the 2026 Tokyo title and three Major runner-up finishes remain the record of a genuinely elite marathoner, while the ban makes her commercially radioactive—in a sport where distance-running sponsorship is already thin. From a broader perspective, this case demonstrates that AIU enforcement has now shifted from "detection" to "document verification." Aga's case is not an outlier—it belongs to a recognizable family of East African road-racing cases where the initial substance violation is compounded by a fabricated or altered explanation. Since the same informal medical networks serve many athletes in the same training clusters, multiple similarly-profiled cases are likely in the pipeline. The Ethiopian federation's response is unknown and unmentioned—only the AIU statement is quoted, with no national-level statement. This is itself a signal that the case is not being taken seriously or is being avoided at the national level. Ultimately, this case is an example of a major failure of sports-medical governance. An athlete with a credentialed team physician would either (a) hold or apply for a Therapeutic Use Exemption (TUE), or (b) observe WADA's route-specific washout period. Neither happened. Instead, a fake prescription was created. This suggests the athlete had neither institutional support nor understanding of the rules—and that gap remains the biggest risk factor in East African road running. The March Chinese half marathon was almost certainly a World Athletics Label road race with an elite women's field and out-of-competition/in-competition testing. Otherwise no AIU test would exist. Her result and prize money from that race are very likely annulled, even though the report does not say so; standard AIU practice is automatic disqualification of the competition where the sample was collected. It remains to be seen whether Aga will appeal to CAS. But even if she does, the forgery finding—with three independent verification failures—is so strong that overturning it is nearly impossible. Her career as an athlete is over; as a sports-ethics case, this one will be cited for a long time.